SEC Filings
West Pharmaceutical Refinanced $203.0 Million Of 2027 Debt Just Before Its Quarterly Report
A new $200 million term loan and $750 million revolver run to 2031, as $685.3 million of buybacks cut cash to $464.1 million.
West Pharmaceutical (WST) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
A new $200 million term loan and $750 million revolver run to 2031, as $685.3 million of buybacks cut cash to $464.1 million.
Markets
The injectable-drug packaging supplier raised its 2026 sales and earnings targets, but guided fourth-quarter growth well below the third quarter.
Earnings
West's CEO and CFO said GLP-1 sales growth had no one-time boost, and guided fourth-quarter revenue to $820 million to $830 million.
Earnings
CEO Michele Lagarde, two months into the job, says West will stay organic and patient while its customers consolidate suppliers.
Earnings
West lifted its full-year sales and adjusted earnings guidance after third-quarter sales rose 8.7% to $874.5 million.
SEC Filings
The injectable-drug packaging maker repaid $130.0 million owed on the old facility and set a $200 million term loan alongside a revolver.